DrugPatentWatch Database Preview

Avapritinib - Generic Drug Details

« Back to Dashboard

What are the generic sources for avapritinib and what is the scope of patent protection?

Avapritinib is the generic ingredient in one branded drug marketed by Blueprint Medicines and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Avapritinib has forty patent family members in thirty countries.

Summary for avapritinib

International Patents:	40
US Patents:	3
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	29
Clinical Trials:	8
Patent Applications:	24
What excipients (inactive ingredients) are in avapritinib?	avapritinib excipients list
DailyMed Link:	avapritinib at DailyMed

Recent Clinical Trials for avapritinib

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Blueprint Medicines Corporation	Phase 1
Blueprint Medicines Corporation	Phase 4
National Cancer Institute (NCI)	Phase 2

See all avapritinib clinical trials

US Patents and Regulatory Information for avapritinib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Blueprint Medicines	AYVAKIT	avapritinib	TABLET;ORAL	212608-002	Jan 9, 2020		RX	Yes	No
Blueprint Medicines	AYVAKIT	avapritinib	TABLET;ORAL	212608-003	Jan 9, 2020		RX	Yes	Yes			Y	Y
Blueprint Medicines	AYVAKIT	avapritinib	TABLET;ORAL	212608-001	Jan 9, 2020		RX	Yes	No
Blueprint Medicines	AYVAKIT	avapritinib	TABLET;ORAL	212608-005	Jun 16, 2021		RX	Yes	No
Blueprint Medicines	AYVAKIT	avapritinib	TABLET;ORAL	212608-002	Jan 9, 2020		RX	Yes	No			Y	Y
Blueprint Medicines	AYVAKIT	avapritinib	TABLET;ORAL	212608-001	Jan 9, 2020		RX	Yes	No			Y	Y

International Patents for avapritinib

Country	Patent Number	Estimated Expiration
Norway	2021012
Mexico	2016004927
Netherlands	301094
Japan	6782756
Lithuania	3057969
European Patent Office	3409674

Supplementary Protection Certificates for avapritinib

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3057969	PA2021003	Lithuania		PRODUCT NAME: AVAPRITINIBAS IR JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS; REGISTRATION NO/DATE: EU/1/20/1473 20200924
3057969	CA 2021 00008	Denmark		PRODUCT NAME: AVAPRITINIB OG FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/20/1473 20200925
3057969	2021C/509	Belgium		PRODUCT NAME: AVAPRITINIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/20/1473 20200925
3057969	LUC00199	Luxembourg		PRODUCT NAME: AVAPRITINIB ET SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/20/1473 20200925
3057969	C20210005 00320	Estonia		PRODUCT NAME: AVAPRITINIIB;REG NO/DATE: EU/1/20/1473 25.09.2020
3057969	301094	Netherlands		PRODUCT NAME: AVAPRITINIB EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/20/1473 20200925